Updated:
BridgeBio
BridgeBio was founded in 2015 by Neil Kumar, a structural biologist and entrepreneur who previously co-founded the cancer drug discovery firm Global Blood...
BridgeBio
BridgeBio was founded in 2015 by Neil Kumar, a structural biologist and entrepreneur who previously co-founded the cancer drug discovery firm Global Blood Therapeutics. The company emerged as a vehicle to bridge the gap between academic genetic insights and clinical-stage assets, operating a centralized hub-and-spoke structure where each subsidiary or program targets a specific disease pathway while sharing development, regulatory, and commercial resources. The firm's strategy spans preclinical to late-stage trials across more than 30 active programs, including therapies for transthyretin amyloidosis (acoramidis, approved in 2024 under the brand Attruby), achondroplasia, and various cancers. BridgeBio also actively in-licenses and acquires assets; in 2023 it acquired the preclinical oncology assets of Remix Therapeutics. Geographically, the firm is headquartered in Palo Alto with additional operations in San Diego and a European subsidiary in Dublin. As of 2025, BridgeBio had raised over $2 billion in equity and debt financing, including a public listing on Nasdaq in 2019. The firm employs roughly 700 people. It also operates a philanthropic arm, the BridgeBio Foundation, which supports patient advocacy and disease research. The company's clinical progress on acoramidis led to FDA approval in November 2024 — a major operational milestone. BridgeBio's structural differentiator is its subsidiary model: each therapeutic program is set up as a separate legal entity, allowing the firm to preserve optionality around partnerships, spinouts, and risk-sharing. This architecture resembles a venture studio more than a traditional biotech, enabling simultaneous pursuit of multiple high-risk targets without diluting the parent balance sheet.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Principals
Neil Kumar
Founder & CEO
Eric Hedrick
Chief Medical Officer
Sector focus
Frequently asked questions
How does BridgeBio's subsidiary model affect its risk profile?
BridgeBio structures each therapeutic program as a separate subsidiary, which limits liability to individual assets and preserves the parent company's balance sheet. This allows the firm to pursue multiple high-risk programs concurrently. It also enables spinning out assets into independent companies if they progress to late stages, as seen with acoramidis.
What sources of funding has BridgeBio used?
BridgeBio has raised over $2 billion through a combination of venture capital, IPO proceeds, and debt financing. The firm went public on Nasdaq in 2019. It has also raised capital via milestone payments and partnerships, including a royalty deal with Blueprint Medicines in 2024. BridgeBio has not disclosed any direct family office or sovereign wealth fund backing.
Has BridgeBio received any FDA approvals?
Yes. In November 2024, the FDA approved BridgeBio's acoramidis (branded Attruby) for the treatment of transthyretin amyloidosis with cardiomyopathy. This marked the firm's first regulatory approval and a key validation of its drug development model.
What therapeutic areas does BridgeBio focus on?
BridgeBio's pipeline spans oncology, cardiology, and rare genetic diseases. The firm targets conditions such as transthyretin amyloidosis, achondroplasia, and various cancers. It uses genetic validation to identify high-probability targets and builds subsidiaries around each mechanism.
Does BridgeBio have any philanthropic structures?
Yes. BridgeBio operates the BridgeBio Foundation, a nonprofit that supports patient advocacy, disease education, and research grants. The foundation is funded by BridgeBio but operates independently, focusing on improving outcomes for patients with genetically defined diseases.
Who leads investment decisions at BridgeBio?
Neil Kumar, founder and CEO, oversees corporate strategy and capital allocation. The firm's management team includes Eric Hedrick as Chief Medical Officer and experienced drug developers. As a publicly traded company, BridgeBio's board of directors also plays a role in major investment and partnership decisions.
Is BridgeBio structured as a family office?
No. BridgeBio is a publicly traded biotechnology company (Nasdaq: BBIO). It operates as a commercial-stage drug developer, not a family office or investment vehicle. Its hybrid model uses a hub-and-spoke structure that resembles a venture firm, but its primary activity is therapeutic development.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: